This dynamic educational activity equips healthcare professionals with practical, up-to-date knowledge to improve outcomes for patients with obstructive hypertrophic cardiomyopathy (oHCM). Participants will evaluate pharmacologic treatments—including cardiac myosin inhibitors—by examining mechanisms of action, side effects, and patient-specific considerations. The program also highlights the critical role of nurses and advanced practice providers in patient assessment, lifestyle education, interdisciplinary care, and medication management. Learners will explore the indications and outcomes of surgical interventions like septal myectomy and gain strategies for recognizing and responding to arrhythmias in oHCM. Guided by experts from a recognized HCM Center of Excellence—with over a decade of experience treating patients and leading clinical trials—participants will gain firsthand insights into best practices in specialized care. Join us to enhance diagnostic accuracy, apply timely interventions, and stay at the forefront of oHCM care.

Registration
Free to all learners 

Once you’ve completed registration, return to the homepage and click on the Begin tab to complete the pre-test before the start of the course.

Credits
AMA PRA Category 1 Credits™ (1.50 hours), AAPA Category 1 CME credits (1.50 hours), ANCC Contact Hours (1.50 hours), Non-Physician Participation Credit (1.50 hours)

Target Audience
Specialties - Cardiology, Cardiovascular Disease, Cardiovascular Health, Interventional Cardiology

Professions - Advance Practice Nurse (APN), Fellow/Resident, Non-Physician, Nurse, Physician, Physician Associate, Registered Nurse (RN)

Objectives
At the conclusion of this activity, learners should be able to:

• Evaluate the effectiveness of different pharmacological treatments for hypertrophic cardiomyopathy, discussing the mechanisms of action, potential side effects, and patient-specific factors that influence therapy selection, including cardiac myosin inhibitors
• Illustrate the role of nurses and advanced practice providers in the care of patients with hypertrophic cardiomyopathy, including patient assessment, education on lifestyle modifications, coordination of interdisciplinary care, and specialty medication management
• Describe the indications, procedures, and outcomes associated with surgical interventions for hypertrophic cardiomyopathy, including septal myectomy
• Interpret the significance of arrhythmias in patients with hypertrophic cardiomyopathy, and propose appropriate clinical responses or interventions based on the identified arrhythmias

Accreditation
In support of improving patient care, Stanford Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 
 
Credit Designation 
American Medical Association (AMA) 
Stanford Medicine designates this Live Activity for a maximum of 1.50 AMA PRA Category 1 Credits^TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

American Nurses Credentialing Center (ANCC) 
Stanford Medicine designates this live activity for a maximum of 1.5 ANCC contact hours.  

American Academy of Physician Associates (AAPA) - Live  Stanford Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This live activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.